Health Care·Life Sciences Tools & Services·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.53 | N/A | -36.95% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.53 | N/A | -36.95% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding future performance without offering specific guidance. They noted ongoing challenges in the current market environment.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company acknowledged challenges in meeting market expectations.
The earnings report indicates that 10X Genomics is facing challenges, as evidenced by the negative EPS surprise. The stock reacted slightly down by 0.36%, reflecting investor concerns about the company's performance and lack of guidance. Without clear revenue figures or future expectations, uncertainty remains high for investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WELLTOWER INC REIT
Jul 31, 2023